BTIG Initiates Coverage On Zevra Therapeutics with Buy Rating, Announces Price Target of $23

Benzinga Newsdesk www.benzinga.com Neutral 49.9%

Neg 0% Neu 49.9% Pos 0%

BTIG analyst Kambiz Yazdi initiates coverage on Zevra Therapeutics (NASDAQ:ZVRA) with a Buy rating and announces Price Target of $23.